scholarly journals Lactating Adenoma Co-Existing with High Grade Invasive Ductal Carcinoma; Collision Tumour or Mere Co-Incidence

2020 ◽  
Vol 5 (12) ◽  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Young Patient ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Positive Family History ◽  
Tumour Cells ◽  
High Grade ◽  
Collision Tumour ◽  
History Of

Background: Lactating adenoma are benign lesions that can presents as a solitary or multiple freely movable breast mass during pregnancy or puerperium. The lesion is actually a localized focus of hyperplasia in the lactating breast, which may also develop in ectopic locations such as the axilla, chest wall, or vulva. Breast cancer developing during pregnancy or puerperium is known as pregnancy associated breast cancer. We report a case of lactating adenoma co-existing with high grade invasive ductal carcinoma in young patient in puerperium with a positive family history of breast cancer. We present a 19-year-old female with a palpable mass on her right upper outer quadrant of her right breast measuring 5x4x2cm with ipsilateral supraclavicular lymph node enlargement. Cytomorphology of the lesion showed tumour cells arranged in nests and solid sheets with abundant fibromyxoid stroma. Also seen are abnormal mitosis and areas of lymphovascular invasion. Proliferating glands are seen lined by cuboidal cells with cytoplasmic vacuolations. Immunohistochemical stain show tumour cells were triple negative (negative for progesterone receptor (PR), estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) and strongly positive for EMA in both tumours. Conclusion: This study indicated that lactating adenoma can co-exist with high grade invasive ductal carcinoma in a young patient in puerperium. The fact that this patient has a positive family history of breast cancer in first degree relative may explain the presentation at a very young age. It may be very difficult to ascertain whether this is a collision tumour or a mere co-incidence of lactating adenoma with breast cancer in this patient.

A Group Therapy Approach to Facilitate Integration of Risk Information for Women at Risk for Breast Cancer

1998 ◽  
Vol 43 (4) ◽  
pp. 375-380 ◽  
Author(s):  
Mary Jane Esplen ◽  
Brenda Toner ◽  
Jonathan Hunter ◽  
Gordon Glendon ◽  
Kate Butler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
At Risk ◽  
Family History ◽  
Group Therapy ◽  
Perceived Risk ◽  
Positive Family History ◽  
Risk Information ◽  
Degree Relative ◽  
Therapy Approach ◽  
History Of

Objective: To describe and illustrate elements of a group counselling approach designed to enhance the communication of risk information on breast cancer (BC) to women with a family history of this disease. Breast cancer is a leading cause of female cancer death. The most important risk factor for BC is a positive family history in at least 1 first-degree relative, and approximately one-third of women with BC have a family history of the disease. Recent evidence suggests that there is a significant psychological impact associated with having a family history of BC, and this may influence the psychological adjustment and response to being counselled for personal risk. New counselling approaches are required. Method: This paper describes a group therapy approach that incorporates principles of supportive-expressive therapy designed to address the emotional impact of being at risk for BC and to promote accuracy of perceived risk. The key elements of the intervention are described along with clinical illustrations from groups that are part of an ongoing study to develop and standardize the group therapy. Conclusion: Qualitative data from the groups suggest that this model of therapy is both feasible and effective.

scholarly journals Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial

2009 ◽  
Vol 27 (30) ◽  
pp. 4939-4947 ◽  
Author(s):  
Heather A. Jones ◽  
Ninja Antonini ◽  
Augustinus A.M. Hart ◽  
Johannes L. Peterse ◽  
Jean-Claude Horiot ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Breast Conserving Therapy ◽  
Local Relapse ◽  
High Grade ◽  
Invasive Tumor ◽  
Boost Dose ◽  
Central Pathology ◽  
Pathology Review

Purpose To investigate the long-term impact of pathologic characteristics and an extra boost dose of 16 Gy on local relapse, for stage I and II invasive breast cancer patients treated with breast conserving therapy (BCT). Patients and Methods In the European Organisation for Research and Treatment of Cancer boost versus no boost trial, after whole breast irradiation, patients with microscopically complete excision of invasive tumor, were randomly assigned to receive or not an extra boost dose of 16 Gy. For a subset of 1,616 patients central pathology review was performed. Results The 10-year cumulative risk of local breast cancer relapse as a first event was not significantly influenced if the margin was scored negative, close or positive for invasive tumor or ductal carcinoma in situ according to central pathology review (log-rank P = .45 and P = .57, respectively). In multivariate analysis, high-grade invasive ductal carcinoma was associated with an increased risk of local relapse (P = .026; hazard ratio [HR], 1.67), as was age younger than 50 years (P < .0001; HR, 2.38). The boost dose of 16 Gy significantly reduced the local relapse rate (P = .0006; HR, 0.47). For patients younger than 50 years old and in patients with high grade invasive ductal carcinoma, the boost dose reduced the local relapse from 19.4% to 11.4% (P = .0046; HR, 0.51) and from 18.9% to 8.6% (P = .01; HR, 0.42), respectively. Conclusion Young age and high-grade invasive ductal cancer were the most important risk factors for local relapse, while margin status had no significant influence. A boost dose of 16 Gy significantly reduced the negative effects of both young age and high-grade invasive cancer.

scholarly journals Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy

Breast Care ◽  
2019 ◽  
Vol 15 (1) ◽  
pp. 14-21 ◽  
Author(s):  
Francesca Pellini ◽  
Eleonora Granuzzo ◽  
Silvia Urbani ◽  
Sara Mirandola ◽  
Marina Caldana ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
High Risk ◽  
Male Breast Cancer ◽  
Brca2 Mutation ◽  
Positive Family History ◽  
Male Breast ◽  
Mutation Carriers ◽  
History Of ◽  
Clinical Records

Background: Male breast cancer (MBC) is a rare disease with a rising incidence trend. The major risk factors related to MBC are a positive family history of breast cancer (BC) and BRCA1/2 mutations, which indicate a relevant genetic role. Methods: In this retrospective series, we enrolled 69 male patients presenting with male breast cancer (MBC) between 01/01/1992 and 31/12/2018, and 26 high-risk not-affected men presenting between 01/01/2016 and 31/12/2018. Participants’ electronic clinical records were reviewed. Patients’ data reported age at diagnosis, tumor characteristics, therapeutic management, and BRCA1/2 status as well as a family history of breast, ovarian, or prostate cancer (PCa) in first-degree relatives. Results: We analyzed 69 MBC patients. Median age was 64 years. The majority of tumors diagnosed were of an early TNM stage. The most frequent histological subtype was invasive ductal carcinoma (76.7%). Hormone receptors were positive in >90% of MBC cases. Nearly all patients underwent modified radical mastectomy or total mastectomy. Adjuvant endocrine therapy was delivered in 59.4%. Among MBC-affected patients, we recorded a high percentage of a positive family history of BC. Mutational analysis for the BRCA1/2 genes was performed in 17 MBC patients; 11.8% were carriers of BRCA2 pathogenic mutations. Among 26 healthy high-risk subjects included in this case series, 4 were BRCA1 mutation carriers and 9 were BRCA2 mutation carriers. Discussion: We evaluated the distribution of clinicopathological characteristics in MBC subjects and assessed the frequency of mutations in the BRCA genes in affected patients and healthy high-risk subjects, with the aim of proposing a surveillance program for BC and PCa.

A retrospective study on breast cancer presentation, risk factors, and protective factors in patients with a positive family history of breast cancer

2020 ◽  
Vol 26 (3) ◽  
pp. 469-473
Author(s):  
Ying Yi Liaw ◽  
Foong Shiang Loong ◽  
Suzanne Tan ◽  
Sze Yun On ◽  
Evelyn Khaw ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Retrospective Study ◽  
Family History ◽  
Protective Factors ◽  
Positive Family History ◽  
History Of

Introducing a new scoring system based on HER2/neu, p53 oncogenes results and mammographic findings for prediction of tumor grade in breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10687-10687
Author(s):  
M. Guity ◽  
M. Mokri ◽  
M. Shakiba ◽  
M. Atri
Keyword(s):  
Breast Cancer ◽  
Invasive Ductal Carcinoma ◽  
Predictive Value ◽  
Scoring System ◽  
Ductal Carcinoma ◽  
Tumor Grade ◽  
High Grade ◽  
Group Iii ◽  
Immunohistochemical Studies ◽  
New Scoring

10687 Background: During recent years, several oncogenes have been introduced in relation to breast cancer including her2 and P53. These are related with initiation, degree of progression, invasion and prognosis of breast cancer. In this research the rate of positivity of these oncogenes in 150 patients with invasive ductal carcinoma is introduced and the correlation of the results of a new scoring system comprised of mammograms, P53 and her2 with the tumor grade is assessed. Methods: 150 cases of invasive ductal carcinoma of a private clinic were chosen. The diagnosis of cancer and its grade was confirmed by pathology. All patients underwent mammography befor surgery and the results were classified according to BIRADS system to benign (groups of I and II in BIRADS): Score I, suspicious (group III in BIRADS): Score II and malignant (groups of IV and V in BIRADS): score III. P53 and her2 presence were assessed by immunohistochemical studies and the results were classified as negative (score I) and positive (score II). The final score of each patients was calculated by adding scores of all three studies (P53, her2, mammography) which ranged between 3 to 7. Results: The average age of the patients was 48.2 + 11.2 years; most of them were between 30–50 years old. Three had benign mammograms (2%), 81 had suspicious (54%) and 66 had malignant findings (44%). We showed positive P53in 59 (39%), positive her2 in 69 (46%) and high grade tumor in 77 (51%) patients. On scoring, 2 patients gained 3 (1.3%), 36 scored 4 (24%), 53 patients received 5 (35.3%), 37 reached 6 scores (24.7%) and 22 patients received 7 scores (14.7%). Placing scores 3 and 4 in one group and scores 5–7 in another, the sensitivity and negative predictive value of the system for high grade tumors reached 97.7% and 89.5% respectively. By placing scores 3–6 in one group and score 7 in another, the specificity and positive predictive value of the system reached to 100%. Conclusions: The results of mammography, P53 and her2 seems to have a good correlation with tumor grade, meaning when all three parameters are positive, the patients’ tumor is almost always high grade. No significant financial relationships to disclose.

scholarly journals Prevalence of germline TP53 mutation among early onset middle eastern breast cancer patients

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Abdul Khalid Siraj ◽  
Tariq Masoodi ◽  
Rong Bu ◽  
Sandeep Kumar Parvathareddy ◽  
Kaleem Iqbal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Early Onset ◽  
Middle Eastern ◽  
Mutation Screening ◽  
Univariate Analysis ◽  
Positive Family History ◽  
Germline Mutations ◽  
Pathogenic Mutations ◽  
History Of

Abstract Background The data on prevalence and clinical relevance of TP53 germline mutations in early onset Middle-Eastern breast cancer (BC) is limited. Methods We determined TP53 germline mutations in a cohort of 464 early onset BC patients from Saudi Arabia using capture sequencing based next generation sequencing. Results Germline TP53 pathogenic mutations were found in 1.5% (7/464) of early onset Saudi BC patients. A total of six pathogenic missense mutations, one stop gain mutation and two variants of uncertain significance (VUS) were detected in our cohort. No TP53 pathogenic mutations were detected among 463 healthy controls. TP53 mutations carriers were significantly more likely to have bilateral breast cancer (p = 0.0008). At median follow-up of 41 months, TP53 mutations were an unfavorable factor for overall survival in univariate analysis. All the patients carrying TP53 mutations were negative for BRCA1 and BRCA2 mutations. Majority of patients (85.7%; 6/7) carrying TP53 mutation had no family history suggestive of Li-Fraumeni Syndrome (LFS) or personal history of multiple LFS related tumors. Only one patient had a positive family history suggestive of LFS. Conclusions TP53 germline mutation screening detects a clinically meaningful risk of early onset BC from this ethnicity and should be considered in all early onset BC regardless of the family history of cancer, especially in young patients that are negative for BRCA mutations.

scholarly journals BREAST CANCER;

2014 ◽  
Vol 21 (06) ◽  
pp. 1128-1132
Author(s):  
Abeer Nisar ◽  
M Naim Siddiqi ◽  
Naveed ur Rehman ◽  
Raza ur Rahman
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Family History ◽  
Menopausal Status ◽  
Positive Family History ◽  
American Woman ◽  
Breast Cancer Patients ◽  
Civil Hospital ◽  
Early Menarche ◽  
History Of

Objective: To assess the risk factors for breast cancer in patients attending oncology OPD of civil hospital Karachi, Pakistan. Introduction: Breast cancer is the single largest cause of death among women1,2. The probability of American woman developing breast cancer in their life is 7 in 11. Studies from subcontinent show that the incidence of breast cancer is increasing, with an estimated 80,000 new cases diagnosed annually. Breast cancer is the second most common type of cancer after lung cancer in Pakistan and ranked first in women. Only 10% women are diagnosed, out of them, 75% women do not get treatment and die within 5 years6. Data from Pakistan about the risk factors or association is not only scanty but also does not comment on the use of fatty diet in breast cancer patients. Method: A cross-sectional descriptive study conducted at Oncology OPD of civil hospital Karachi (CHK) from October 2009 -April 2011. One Hundred and Fifty consecutive patients having histopathalogical diagnosis of breast cancer were assessed for different risk factors that included marital status, parity, age, menopausal status, family history of breast cancer, prolong use of oral contraceptives, breast feeding, , early menarche, trauma to the breast and fatty diet. Result: Mean age of patients was 48 years. Three fourth (73%) of these female were above the age of 40 years. Consumption of fatty diet was found in 62.67% while positive family history of breast cancer was present in 34% of the cases. Early menarche and being nulliparous were not as strong risk factors as in previous studies. Conclusions: Our study has highlighted the need of further exploration in this area that would not only help this population but also enhance our understanding of different risk factors. This will have important implications for the overall management of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document